ISIS Pharmaceuticals Sues Santaris Pharma

September 27, 2011

ISIS Pharmaceuticals filed suit against Santaris Pharma over two patents related to modified oligonucleotides and antisense modulation of beta catenin expression.  9/22, Southern District of California, 3:2011cv02214.

Access to the full article is currently available to RPX members only. Please contact us if you need further information.

Related News